Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam | Zendy

Melissa D. Barnes | Zendy; Christopher R. Bethel | Zendy; Jim Alsop | Zendy; Scott A. Becka | Zendy; Joseph Rutter | Zendy; Krisztina M. PappWallace | Zendy; Robert A. Bonomo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam

Author(s) -

Melissa D. Barnes,

Christopher R. Bethel,

Jim Alsop,

Scott A. Becka,

Joseph Rutter,

Krisztina M. PappWallace,

Robert A. Bonomo

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02406-17

Subject(s) - pseudomonas , microbiology and biotechnology , pseudomonadales , pseudomonadaceae , chemistry , bacteria , biology , genetics

Pseudomonas aeruginosa is a prevalent and life-threatening Gram-negative pathogen.Pseudomonas -derived cephlosporinase (PDC) is the major inducible cephalosporinase inP. aeruginosa . In this investigation, we show that relebactam, a diazabicyclooctane β-lactamase inhibitor, potently inactivates PDC-3, with ak 2 /K of 41,400 M−1 s−1 and ak off of 0.00095 s−1 . Relebactam restored susceptibility to imipenem in 62% of multidrug-resistantP. aeruginosa clinical isolates, while only 21% of isolates were susceptible to imipenem-cilastatin alone. Relebactam promises to increase the efficacy of imipenem-cilastatin againstP. aeruginosa .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research